Projects per year
Fingerprint
Dive into the research topics where Richard Geoffrey Vile is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 10 Finished
-
Mayo Clinic Hepatobiliary SPORE
Mc Niven, M. M. A., Alberts, S. R., Gores, G. J., Leof, E. B., Roberts, L. R., Mandrekar, S. J., Torbenson, M., Vile, R. G. & Yin, V.
9/10/18 → 8/31/23
Project: Research project
-
-
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
1/1/09 → 11/30/14
Project: Research project
-
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm
7/1/08 → 5/31/14
Project: Research project
-
Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors
7/1/05 → 11/30/14
Project: Research project
-
Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression
Tritz, Z. P., Ayasoufi, K., Wolf, D. M., Owens, C. A., Malo, C. S., Himes, B. T., Fain, C. E., Goddery, E. N., Yokanovich, L. T., Jin, F., Hansen, M. J., Parney, I. F., Wang, C., Moynihan, K. D., Irvine, D. J., Wittrup, K. D., Diaz Marcano, R. M., Vile, R. G. & Johnson, A. J., Jun 1 2023, In: Cancer Immunology Research. 11, 6, p. 763-766 4 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
Smith, K. E. R., Peng, K. W., Pulido, J. S., Weisbrod, A. J., Strand, C. A., Allred, J. B., Newsom, A. N., Zhang, L., Packiriswamy, N., Kottke, T., Tonne, J. M., Moore, M., Montane, H. N., Kottschade, L. A., McWilliams, R. R., Dudek, A. Z., Yan, Y., Dimou, A., Markovic, S. N., Federspiel, M. J., & 3 others , 2023, In: Frontiers in immunology. 14, 1279387.Research output: Contribution to journal › Article › peer-review
Open Access -
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
Nagalo, B. M., Zhou, Y., Loeuillard, E. J., Dumbauld, C., Barro, O., Elliott, N. M., Baker, A. T., Arora, M., Bogenberger, J. M., Meurice, N., Petit, J., Uson, P. L. S., Aslam, F., Raupach, E., Gabere, M., Basnakian, A., Simoes, C. C., Cannon, M. J., Post, S. R., Buetow, K., & 9 others , Jun 2023, In: Hepatology. 77, 6, p. 1943-1957 15 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
Webb, M. J., Sener, U. & Vile, R. G., Jun 2023, In: Pharmaceuticals. 16, 6, 793.Research output: Contribution to journal › Review article › peer-review
Open Access -
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition
Miley, D. R., Andrews-Pfannkoch, C. M., Pulido, J. S., Erickson, S. A., Vile, R. G., Fautsch, M. P., Marmorstein, A. D. & Dalvin, L. A., Dec 1 2023, In: Melanoma research. 33, 6, p. 482-491 10 p.Research output: Contribution to journal › Article › peer-review